Striatal calcium channel antagonist receptors in Huntington's disease and Parkinson's disease.
The density of calcium channel antagonist receptors labeled by (+)-[3H]PN 200-110 was reduced by 75% in striata from patients with Huntington's disease, but unchanged in patients with Parkinson's disease, compared with control subjects. These receptors are therefore likely to be localized to neurons with cell bodies in striatum, rather than nigrostriatal nerve terminals or glia, and their loss may contribute to the pathophysiology of basal ganglia disorders.
Watson
D L
DL
Department of Neurology, University of California, San Francisco.
Carpenter
C L
CL
Marks
S S
SS
Greenberg
D A
DA
D000368:Aged; D002121:Calcium Channel Blockers / Q000378:metabolism*; D003342:Corpus Striatum / Q000473:pathology*; D006801:Humans; D006816:Huntington Disease / Q000473:pathology*; D017275:Isradipine; D008875:Middle Aged; D009410:Nerve Degeneration; D009434:Neural Pathways / Q000473:pathology; D009474:Neurons / Q000473:pathology; D010069:Oxadiazoles / Q000378:metabolism; D010300:Parkinson Disease / Q000473:pathology*; D013378:Substantia Nigra / Q000473:pathology
D002121:Calcium Channel Blockers; D010069:Oxadiazoles; D017275:Isradipine